Breakthrough in Genetic Disorder Treatment: GC Pharma’s Sanfilippo Syndrome Drug Receives FDA Phase 1 Approval
[su_heading size=”27″ align=”left” margin=”40″]Introduction to Sanfilippo Syndrome and GC Pharma’s Efforts[/su_heading] Sanfilippo Syndrome, also known as Mucopolysaccharidosis Type III, is a rare genetic disorder caused by the body’s inability to produce an enzyme necessary for breaking down heparan sulfate. This accumulation leads to severe organ damage and developmental delays. GC Pharma, in collaboration with biotech … Read more